KP-1461
Reverse transcriptase inhibitor | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
JSmol) | |
| |
|
This article may be too technical for most readers to understand.(March 2021) |
KP-161 is an experimental antiviral drug being studied for the treatment of
nucleoside reverse transcriptase inhibitors.[citation needed
]
KP-1461 is a prodrug of the active antiviral agent KP-1212.[2]
References
- ^ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
- ^ "KP-1461". DrugBank. Canadian Institutes of Health Research.